Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Mass Balance of [14C]TAS-205 in Healthy Volunteers
NCT04825431Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pizuglanstat in Duchenne muscular dystrophy (DMD), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics parameters of TAS-205, Radioactivity excretion and excretion rate and 2 more. Started Mar 2021; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04825431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825431.